Kadmon Holdings, Inc. (NYSE:KDMN) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.

According to Zacks, “Kadmon Holdings, Inc. is a biopharmaceutical company. It engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. The company is developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases. Kadmon Holdings, Inc. is headquartered in New York. “

Other research analysts have also issued research reports about the stock. Piper Jaffray Companies set a $7.00 target price on shares of Kadmon Holdings and gave the stock a “buy” rating in a research report on Wednesday, August 2nd. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price objective on shares of Kadmon Holdings in a research report on Friday, November 17th. WBB Securities lowered shares of Kadmon Holdings from a “hold” rating to a “sell” rating and set a $3.00 price objective for the company. in a research report on Monday, October 9th. Finally, ValuEngine lowered shares of Kadmon Holdings from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 1st. Two analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $9.75.

Kadmon Holdings (NYSE KDMN) opened at $3.59 on Tuesday. Kadmon Holdings has a 52-week low of $2.05 and a 52-week high of $5.96.

Kadmon Holdings (NYSE:KDMN) last released its earnings results on Thursday, November 9th. The company reported ($0.42) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.38) by ($0.04). The business had revenue of $2.28 million for the quarter, compared to analysts’ expectations of $5.69 million. Kadmon Holdings’s revenue was down 60.0% on a year-over-year basis. During the same period last year, the company posted ($4.24) earnings per share. equities analysts predict that Kadmon Holdings will post -1.63 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This news story was first reported by Watch List News and is owned by of Watch List News. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://www.watchlistnews.com/zacks-investment-research-upgrades-kadmon-holdings-inc-kdmn-to-hold/1718624.html.

In other news, major shareholder Goldentree Asset Management Lp sold 302,950 shares of the company’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $2.73, for a total transaction of $827,053.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 8.41% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of KDMN. Bank of New York Mellon Corp increased its stake in Kadmon Holdings by 302.3% in the first quarter. Bank of New York Mellon Corp now owns 46,304 shares of the company’s stock valued at $167,000 after acquiring an additional 34,794 shares during the period. JPMorgan Chase & Co. increased its stake in Kadmon Holdings by 11,654.8% in the first quarter. JPMorgan Chase & Co. now owns 228,866 shares of the company’s stock valued at $829,000 after acquiring an additional 226,919 shares during the period. Renaissance Technologies LLC bought a new stake in Kadmon Holdings in the first quarter valued at about $158,000. KCG Holdings Inc. bought a new stake in Kadmon Holdings in the first quarter valued at about $124,000. Finally, Sawtooth Solutions LLC increased its stake in Kadmon Holdings by 396.9% in the second quarter. Sawtooth Solutions LLC now owns 99,649 shares of the company’s stock valued at $388,000 after acquiring an additional 79,593 shares during the period. 27.96% of the stock is currently owned by institutional investors and hedge funds.

Kadmon Holdings Company Profile

Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.

Receive News & Ratings for Kadmon Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.